2. Disease Areas
  3. Urogenital Disease
  4. Urogenital Cancer
  5. Endometrial Cancer

Endometrial Cancer

Endometrial cancer is a malignancy that originates in the endometrium, the inner lining of the uterus, and is primarily composed of adenocarcinomas arising from mucus-producing cells. It is the most common cancer of the female reproductive system and typically occurs after menopause. Key symptoms include abnormal vaginal bleeding—such as postmenopausal bleeding, intermenstrual bleeding, or heavy, prolonged menstrual periods—as well as abnormal vaginal discharge, pelvic pain, or discomfort during intercourse or urination. Major risk factors include obesity, metabolic syndrome, early menarche, nulliparity, and a family history of the disease. While there is no guaranteed prevention method, maintaining a healthy weight through diet and exercise may reduce risk. Treatment options depend on the stage and subtype but commonly involve surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Endometrial Cancer (6):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P3371
    Ifinatamab deruxtecan 2484870-92-8 99.29%
    Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects
    Ifinatamab deruxtecan
  • HY-16441
    Tegafur-gimeracil-oteracil potassium 150863-82-4 99.96%
    Tegafur-gimeracil-oteracil potassium (S-1; TS-1) is an orally active anticancer agent composed of Tegafur (HY-17400), Gimeracil (HY-17469), and Oteracil potassium (HY-17511). Tegafur-gimeracil-oteracil potassium inhibits the proliferation, migration and invasion of endometrial cancer cells and induces apoptosis by blocking the PI3K/AKT/mTOR signaling pathway. Tegafur-gimeracil-oteracil potassium can be used in research related to endometrial cancer and gastric cancer with peritoneal metastasis.
    Tegafur-gimeracil-oteracil potassium
  • HY-P990704
    Rilvegostomig 2640305-01-5 99.00%
    Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer.
    Rilvegostomig
  • HY-P991971
    ONCR-201
    ONCR-201 (PG-101) is a fully human monoclonal antibody targeting epithelial membrane protein 2 (EMP2). ONCR-201 is applicable to research related to breast cancer, ovarian cancer, and endometrial cancer.
    ONCR-201
  • HY-181074
    Tubulin polymerization-IN-88
    Tubulin polymerization-IN-88 is a tubulin inhibitor that blocks tubulin polymerization, leading to microtubule destabilization and disruption of the mitotic spindle. Tubulin polymerization-IN-88 induces G2/M phase arrest and apoptosis in cancer cells, and inhibits cancer cell migration and self-renewal of cancer stem cells. It exhibits in vitro anti-proliferative activity against cancer cells with selectivity over normal cells. Tubulin polymerization-IN-88 also demonstrates in vivo anti-cancer activity without significant toxicity. Tubulin polymerization-IN-88 is applicable for research on glioblastoma, lung cancer, endometrial cancer, ovarian cancer, and leukemia.
    Tubulin polymerization-IN-88
  • HY-176912
    WRN-IN-22
    WRN-IN-22 (compound A01) is a potent Werner syndrome RecQ helicase (WRN) inhibitor (IC50 < 100 nM). WRN-IN-22 can be used for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer research, such as colorectal, gastric, prostate and endometrial cancer.
    WRN-IN-22